Oncopeptides surges on positive EU market news for Pepaxti

Oncopeptides, a cancer pharma firm whose stock had collapsed, rose double digits after announcing positive European market developments for its drug Pepaxti. The specific nature of the news is not detailed, and the sustainability of the move is uncertain given the company's prior decline.